Regulators speed review of Merck's Hep C drug; EMA approves Lucentis for wider use;

 @FierceBiotech:  Biogen Idec taps two ex-CEOs to head R&D, corporate development. Story | Follow @FierceBiotech

 @JohnCFierce: I really want to see the FDA deliver those CRL letters to the public. Long, long overdue. | Follow @JohnCFierce

> European and American regulators will expedite their review of Merck's Hepatitis C treatment, boceprevir. The FDA hopes to finish its review in six months. Article

> The University of Maryland will double the size of its for-rent biotech lab facilities, which have been used by MedImmune and Human Genome Sciences. The lab brings $300,000 in annual revenue to the university and has helped Digene and Martek Biosciences grow into billion-dollar biotech companies. News

> Novartis got some good news from the EMA today. Its eye drug Lucentis has been approved for wider usage in patients suffering visual impairment from diabetic macular edema, a leading cause of blindness in adults. Report

> BIND Biosciences has started a Phase I clinical trial for a cancer treatment nanoparticle: BIND-014. The targeted polymeric nanoparticle contains docetaxil, and, according to preclinical trials, can deliver 20 times more docetaxil than an equivalent dosage of Taxotere, which also uses docetaxil. BIND release

> Three Boston-area biotech companies received $1 million grants from the Multiple Myeloma Research Foundation for multiple myeloma drug development. The three companies are Constellation Pharmaceuticals, Epizyme and Karyopharm Therapeutics. MMRF release

> Animal health company Aratana Therapeutics closed a $20 million Series A financing round led by Avalon Ventures and MPM Capital. Aratana release

And Finally... It's official: Women's tears can trigger a sudden drop in testosterone. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.